

**From:** [Gaskins, Farrah](#)  
**To:** [Sciore, Kelly A. \(Kelly.Sciore@nemours.org\)](mailto:Kelly.Sciore@nemours.org)  
**Subject:** Request for Additional Information for License No. 07-16199-02  
**Date:** Monday, April 20, 2015 2:36:00 PM

---

Licensee: Nemours A.I. DuPont Hospital for Children.  
License No.: 07-16199-02  
Docket No.: 030-19939  
Control No.: 585713

Dear Ms. Sciore:

**Please send a return email to confirm that you received this message.**

This is in reference to the application December 31, 2014 requesting to renew Nuclear Regulatory Commission License No. 07-16199-02. In order to complete your renewal application, we need the following additional information:

1. Your application should have been signed by a management representative rather than the RSO. Please submit a letter signed by a management representative indicating that management has reviewed the application and concurs in the statements and representations contained therein. Note also that a management representative should sign all future correspondence that requests a change in your license.
2. Your current license lists the mailing address as 1600 Rockland Road, P.O. Box 269, Wilmington, Delaware 19899. In section 3 of your application the mailing address is 1600 Rockland Road, Wilmington, DE 19803. Please confirm which address should be listed as the mailing address in License Condition number 2 of your license.
3. Your current license authorizes Technetium 99m for verification of shielding. Please confirm if you wish to maintain the authorization for 100 millicuries of Technetium 99m.
4. In your application, you requested materials with mass number 3-203. Please specify the radioisotopes you wish to use and the purpose for which you plan to use them. In addition, identify an authorized user for these materials and submit documentation of training and experience for that individual for the additional types and quantities of materials.
5. Confirm if the request for 35.100 and 25.200 will NOT include the use of Positron Emission Tomography (PET) radiopharmaceuticals.
6. Please confirm that you will develop, implement and maintain **written** procedures for the safe use of unsealed byproduct materials that meet the requirements of 10 CFR 20.1101 and 20.1301.

Current NRC regulations and guidance are included on the NRC's website at [www.nrc.gov](http://www.nrc.gov);

select Nuclear Materials; Med, Ind, & Academic Uses; then Licensee Toolkits, see our toolkit index page. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

You may respond to my attention in writing by letter, email (if scanned into a pdf format), or fax (610-337-5269), referencing mail control number 585713. Please ensure that your response is signed by an appropriate licensee management representative.

If we do not receive a reply from you within 30 days, we will assume that you do not wish to pursue your amendment. Please feel free to contact me with any questions you may have.

*Farrak C. Gaskins*

Health Physicist  
U.S. NRC, Region 1  
2100 Renaissance Blvd, Suite 100  
King of Prussia, PA 19406  
(610) 337-5143 office  
(610) 337-5269 fax